Physician profile
Arinze P Ejiofor
NPI 1699236034
$4,065.11
in general payments reported to CMS, 2019-2025
16 companies · $2,101 in 2025
The $2,101 reported for 2025 was more than what 93% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $221 · 2023: $432 · 2024: $1,311 · 2025: $2,101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,615 · Education: $229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,615.29 |
| Education | $228.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $987.96 | 2022-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $632.87 | 2023-2025 | Qelbree |
| Neurocrine Biosciences, INC. | $380.06 | 2023-2025 | Ingrezza |
| Abbvie INC. | $348.33 | 2023-2025 | |
| Alkermes, INC. | $335.11 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $309.44 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Collegium Pharmaceutical, INC. | $248.82 | 2025 | Jornay Pm |
| Corium, LLC | $196.65 | 2023-2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $172.79 | 2024-2025 | Fanapt |
| Teva Pharmaceuticals USA, INC. | $134.60 | 2024-2025 | Uzedy, Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $96.03 | 2023-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $79.00 | 2023 | Invega Sustenna |
| Lundbeck LLC | $47.74 | 2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $42.76 | 2025 | Cobenfy |
| Tempus Ai, INC | $28.24 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $24.71 | 2024 | Secuado, Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arinze Ejiofor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.